Amedisys (AMED)
(Delayed Data from NSDQ)
$97.21 USD
+0.06 (0.06%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $97.18 -0.03 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Price, Consensus and EPS Surprise
AMED 97.21 +0.06(0.06%)
Will AMED be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AMED based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMED
Waters (WAT) Q2 Earnings & Sales Beat Estimates, Fall Y/Y
Philips (PHG) Q2 Earnings Rise, Revenues Fall Year Over Year
AMED: What are Zacks experts saying now?
Zacks Private Portfolio Services
AMED vs. USPH: Which Stock Is the Better Value Option?
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Down
Compared to Estimates, Amedisys (AMED) Q2 Earnings: A Look at Key Metrics
Other News for AMED
Amedisys sale to UnitedHealth unlikely to be done until at least end of November
BrightSpring Health Services: Evaluating The Investment Case Seven Months Post-IPO
Contessa Selected by Centers for Medicare & Medicaid Services to Test Medicare Dementia Care Model
Top Merger Stocks Held By Fund Managers, Mid-Q3 2024
Amedisys just downgraded at Deutsche Bank, here's why